Merck & Co. Stock News

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed...

In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Merck & Co. NYSE: MRK has committed a formidable $9.2 billion in cash to acquire Cidara Therapeutics NASDAQ: CDTX.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

Dow Jones drug giant Merck is breaking out past its latest buy point as the stock market volatility continues Tuesday.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2026 Dividend.

Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.